Ursodeoxycholyl Lysophosphatidyletanolamide (UDCA-LPE) modifies aberrant lipid profiles in non-alcoholic fatty liver disease

Hepatic fat accumulation with disturbed lipid homeostasis is a characteristic hallmark of non-alcoholic fatty liver disease (NAFLD). Previous work implicated a role for altered lipid composition in the pathophysiology of NAFLD. The bile-acid phospholipid conjugate Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a novel anti-inflammatory agent, which exerted hepatoprotective effects in murine high fat diet (HFD)-induced NAFLD with reduction of lipid overloading and suppression of de novo lipogenesis. The aim of the study was to perform lipidomic analysis in order to study changes in free fatty acid (FF…